Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Integrins protect cardiomyocytes from ischemia/reperfusion injury
Hideshi Okada, … , Joshua I. Goldhaber, Robert S. Ross
Hideshi Okada, … , Joshua I. Goldhaber, Robert S. Ross
Published September 16, 2013
Citation Information: J Clin Invest. 2013;123(10):4294-4308. https://doi.org/10.1172/JCI64216.
View: Text | PDF
Research Article Cardiology

Integrins protect cardiomyocytes from ischemia/reperfusion injury

  • Text
  • PDF
Abstract

Ischemic damage is recognized to cause cardiomyocyte (CM) death and myocardial dysfunction, but the role of cell-matrix interactions and integrins in this process has not been extensively studied. Expression of α7β1D integrin, the dominant integrin in normal adult CMs, increases during ischemia/reperfusion (I/R), while deficiency of β1 integrins increases ischemic damage. We hypothesized that the forced overexpression of integrins on the CM would offer protection from I/R injury. Tg mice with CM-specific overexpression of integrin α7β1D exposed to I/R had a substantial reduction in infarct size compared with that of α5β1D-overexpressing mice and WT littermate controls. Using isolated CMs, we found that α7β1D preserved mitochondrial membrane potential during hypoxia/reoxygenation (H/R) injury via inhibition of mitochondrial Ca2+ overload but did not alter H/R effects on oxidative stress. Therefore, we assessed Ca2+ handling proteins in the CM and found that β1D integrin colocalized with ryanodine receptor 2 (RyR2) in CM T-tubules, complexed with RyR2 in human and rat heart, and specifically bound to RyR2 amino acids 165–175. Integrins stabilized the RyR2 interdomain interaction, and this stabilization required integrin receptor binding to its ECM ligand. These data suggest that α7β1D integrin modifies Ca2+ regulatory pathways and offers a means to protect the myocardium from ischemic injury.

Authors

Hideshi Okada, N. Chin Lai, Yoshitaka Kawaraguchi, Peter Liao, Jeffrey Copps, Yasuo Sugano, Sunaho Okada-Maeda, Indroneal Banerjee, Jan M. Schilling, Alexandre R. Gingras, Elizabeth K. Asfaw, Jorge Suarez, Seok-Min Kang, Guy A. Perkins, Carol G. Au, Sharon Israeli-Rosenberg, Ana Maria Manso, Zheng Liu, Derek J. Milner, Stephen J. Kaufman, Hemal H. Patel, David M. Roth, H. Kirk Hammond, Susan S. Taylor, Wolfgang H. Dillmann, Joshua I. Goldhaber, Robert S. Ross

×

Figure 11

The β1D cytoplasmic domain stabilizes RyR2; integrin heterodimers require ECM binding for RyR2 stabilization.

Options: View larger image (or click on image) Download as PowerPoint
The β1D cytoplasmic domain stabilizes RyR2; integrin heterodimers requir...
(A) FRET image of RyR2S437-YFP/S2367-CFP expressed alone or with α7, β1A, or β1D integrin (original magnification, ×63). (B) Graphic FRET ratio. Relative signal detected in the RyR2-transfected cells was set as 1. FRET signal detected in other samples is displayed relative to control. The RyR2 sensor FRET ratio was increased by dantrolene, an RyR2 stabilizer. β1D integrin cotransfected with the sensor increased the FRET ratio, indicating increased RyR2 stability. No change was seen with α7 or β1A integrin (*P < 0.05 vs. RyR2-transfected cells, n = 20 cells per group). (C) Western blots of control and β1D integrin stably transfected OE cells (OE). β1D integrin precursor (P) was substantially increased in OE cells, but the higher MW mature (M) form increased minimally. No β1D integrin was detected in untransfected cells. GAPDH was used as a loading control. (D) Graphic FRET ratio. FRET ratio in β1D OE cells transiently transfected with RyR2 alone and plated without ECM was set as 1. FRET detected in other samples is displayed relative to this amount. Cells expressing β1D integrin alone showed no change in FRET signal regardless of ECM coating, indicating that there was no stabilization of RyR2. With OE of the FN-binding integrin α5β1D and plating on FN matrix, a stronger FRET signal was found compared with cells plated on LN or no substrate. Cells expressing the LN-binding α7β1D integrin had the most robust FRET signal when plated on LN (*P < 0.05 vs. β1D OE cells transfected with RyR2 alone).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts